500 patients67,039 observations150 daysLIVE

Patient P-03049

Synthetic patientONX-7 · Day 139 · 55–64 · F · baseline S14Steering view · 3DOpen companion preview
Therapy response
Improving
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
74%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 ONX-7 startedBaseline state S14
  2. Day 53 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 61 GI-04 recommendedGI Support Protocol GI-04
  4. Day 62 Patient acceptedStarted GI-04 in the companion
  5. Day 70 GI symptom burden −21% vs expectedGI Support Protocol GI-04
  6. Day 76 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 53.

Primary contributors, last 14 days
  • Inflammatory activity+6
  • Treatment adherence-6
  • Toxicity+6
  • Nutritional resilience-2

What helped?

  • GI Support Protocol GI-04Day 61
    Result: symptom burden −21%
LIFE OS recommendation
Supportive Compound SC-12
70%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 88% showed improvement
  • median effect visible after 6 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Energy level
Daily log
2.9/10
worsening · -1.0 vs previous 14 d
Stress level
Daily log
6.8/10
worsening · +0.8 vs previous 14 d
Pessimism score
Daily log
6.7/10
worsening · +0.5 vs previous 14 d
Sleep quality
Wearable
18.6/100
worsening · -7.7 vs previous 14 d
Libido
Daily log
2.5/10
worsening · -0.7 vs previous 14 d
HRV
Wearable
26.5 ms
worsening · -2.2 vs previous 14 d
Toxicity
Blood
49.6/100
worsening · +6.4 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards restoration · 28 from the failing basin, 63 from restoration.

Would help
  • ME-01 Monitoring Escalation
    100% improved among 11 similar · onset 3 d · confidence 66%
  • SC-12 Supportive Compound
    89% improved among 9 similar · onset 6 d · confidence 66%
  • NP-02 Dietary Support Protocol
    57% improved among 14 similar · onset 10 d · confidence 66%
  • More protein
    GI -4.6 next day on high-intake days · n 16
  • More alcohol
    GI -2.8 next day on high-intake days · n 20
Would not help
  • AD-05 Adherence Support
    only 27% improved among 11 similar
  • Keep histamine low
    GI +5.1 next day on high-intake days · n 22
  • Keep fat low
    GI +5 next day on high-intake days · n 18
  • Keep lactose low
    GI +3.1 next day on high-intake days · n 20
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Histamine load
    +5.1detractor · 95%
  • Dietary fat load
    +5detractor · 95%
  • Protein
    -4.6supporter · 95%
  • Lactose
    +3.1detractor · 69%
  • Alcohol
    -2.8supporter · 60%
  • Caffeine
    -0.8no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Inflammatory signalling 85
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 60
    • WearableHRV 27 ms, trending down
  • Mucosal barrier integrity 60
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • Daily logGI symptom score 59 and rising
    • WearableSleep 6.0 h, below personal baseline
  • Butyrate / short-chain fatty acid production 55
    • MicrobiomeButyrate capacity 39/100
    • Daily logFibre intake low in recent food logs
  • Autonomic recovery 45
    • WearableResting HR 74 bpm
    • WearableShort sleep window
  • Drug metabolism and exposure 20
    • BloodToxicity index 50
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Intermediate metabolizer
    Expected exposure
Microbiome
Shannon diversity 2.9 · butyrate capacity 39/100
  • Akkermansia muciniphilaNormal
  • Faecalibacterium prausnitziiNormal
  • Bacteroides fragilisHigh
  • Bifidobacterium longumLow
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
27 ms
Sleep
5.3 h
Steps
4,760
Resting HR
75 bpm
Daily log: GI score 59, nutritional resilience 38, adherence 43.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0334159%S14NP-02improved49
P-0332351%S14GI-04improved48
P-0303748%S14NP-02improved43
P-0308147%S10GI-04improved53
P-0329347%S14GI-04no change41
P-0339047%S14ME-01improved41
P-0343046%S14SC-12improved45
P-0312344%S14GI-04improved50
P-0334543%S14SC-12improved56
P-0300342%S08SC-12improved53
P-0303041%S14NP-02improved43
P-0309041%S02GI-04improved48